The identification of TNBC-specific antigens such as Trop2 and LIV-1 could also lead to an efficient immunotherapy approach to treat TNBC, similar to CD19-CD3 bsAb for pre-B ALL treatment. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.